Clinical trial NCT03298399: Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease
Official title: A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Sickle Cell Disease
Keywords: Hematopoietic cell transplantation (HCT)
Haploidentical
Mesenchymal stromal cells
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2017-10-02
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This trial is being conducted as a step toward testing the long-term hypothesis that freshly cultured, autologous mesenchymal stromal cells (MSCs) grown in platelet lysate-containing medium will modulate recipient T-cell immune responses and promote engraftment in haploidentical hematopoietic cell transplant (HCT) recipients. As a phase I, dose escalation trial of autologous MSCs in patients with sickle cell disease (SCD) undergoing haploidentical HCT, the main aim is to evaluate the safety of this therapy with a secondary aim to evaluate its effects on engraftment and graft-versus-host disease (GVHD).

Detailed description: This is a single center, phase I, open label dose escalation study designed to determine the safety and tolerability of autologous, bone marrow-derived MSCs (EPIC2016-MSC003) in patients with SCD undergoing haploidentical HCT.

Study participants are assigned to one of three MSC dose levels: four infusions of MSCs given once per week, four infusions given twice per week, or six infusions given twice per week. Bone marrow (1-2 ml/kg, max 60 ml) will be collected from study participants for autologous MSC expansion a minimum of 28 days prior to first planned MSC infusion. MSCs will be expanded ex vivo in human platelet lysate to the specified dose level. All MSC infusions will be dosed at 2 x 10\^6 MSCs/kg recipient weight, with first infusion given on day 0 (day of haploidentical HCT) or day +1. This phase I trial will enroll 12-18 patients with severe SCD undergoing haploidentical HCT, with subjects followed for 1 year following HCT (and MSC infusions).

Prior to MSC infusions, study participants will undergo transplant conditioning and GVHD prophylaxis as follows:

Day -100 to -10: Hydroxyurea 30 mg/kg PO Qday

Day -9: Rabbit anti-thymocyte globulin (ATG) 0.5 mg/kg IV

Day -8: Rabbit ATG 2 mg/kg IV

Day -7: Rabbit ATG 2 mg/kg IV; Thiotepa 10 mg/kg IV

Day -6: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV

Day -5: Fludarabine 30 mg/m2 IV; Cyclophosphamide 14.5 mg/kg IV

Day -4: Fludarabine 30 mg/m2 IV

Day -3: Fludarabine 30 mg/m2 IV

Day -2: Fludarabine 30 mg/m2 IV

Day -1: Total body irradiation (TBI) 200 centigray (cGy)

Day 0: Haploidentical bone marrow stem cell infusion

Day +3: Cyclophosphamide 50 mg/kg IV

Day +4: Cyclophosphamide 50 mg/kg IV

Day +5: Sirolimus (through day +365); mycophenolate mofetil (MMF) 15 mg/kg/dose three times per day (TID) (through day +35)

Eligibility criteria: Inclusion Criteria:

* Must weigh \>25 kg at the time of study entry.
* Must have undergone puberty at the time of study entry to allow pre-transplant fertility preservation to occur, if desired. Puberty will be defined as Tanner III or more in male patients (typically age ≥ 13 years) and menarche in female patients.
* Have severe sickle cell disease (SCD) defined as 1 or more of the following:

  1. Clinically significant neurologic event (stroke) or any neurological deficit lasting \> 24 hours;
  2. History of ≥2 episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea);
  3. History of ≥3 severe pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea);
  4. Administration of regular red blood cell (RBC) transfusion therapy, defined as receiving ≥8 transfusions per year for ≥1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome);
  5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥2.7 m/sec in adult patients.
* Have adequate physical function as measured by:

  1. Lansky or Karnofsky performance score ≥60
  2. Cardiac function: left ventricular ejection fraction (LVEF) \>40% or LV shortening fraction \> 26% by cardiac echocardiogram or by multigated acquisition (MUGA) scan.
  3. Pulmonary function: pulse oximetry with a baseline O2 saturation of ≥90% and DLCO \>40% (corrected for hemoglobin)
  4. Renal function: serum creatinine ≤1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance \>70 mL/min/1.73 m2 or glomerular filtration rate (GFR) \>70 mL/min/1.73 m2 by radionuclide GFR.
  5. Hepatic function: serum conjugated (direct) bilirubin \<2x upper limit of normal for age as per local laboratory and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<5x upper limit of normal as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.
  6. In patients who have received chronic transfusion therapy for ≥1 year and who have clinical evidence of iron overload by serum ferritin or MRI, evaluation by liver biopsy is required. Histological examination of the liver must document the absence of cirrhosis, bridging fibrosis and active hepatitis. The absence of bridging fibrosis will be determined using the histological grading and staging scale as described by Ishak and colleagues (1995).
* Must be HLA typed at high resolution using DNA based typing at HLA-A, -B, -C and DRB1 and have an available related haploidentical bone marrow donor with 2, 3, or 4 (out of 8) HLA-mismatches. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch.

Exclusion Criteria:

* Availability of an 8 of 8 (HLA-A, B, C and DRB1) human leukocyte antigen (HLA) matched sibling or matched unrelated donor
* Presence of donor directed HLA antibodies.
* Severe pulmonary disease (despite above oxygen saturation and DLCO) including severe and uncontrolled asthma (per 2007 NHLBI Guidelines for the Diagnosis and Treatment of Asthma Expert Panel Report 3; http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report), chronic obstructive pulmonary disease, and/or pulmonary hypertension (PH). A diagnosis of pulmonary hypertension (PH) will be made by finding of mean pulmonary artery pressure (mPAP) \<25 mm Hg on right heart catheterization. In patients unable and/or unwilling to undergo cardiac catheterization, patients will be excluded with the following constellation of findings based upon presumptive diagnosis of PH (PPV of 62%): TRJ velocity \>2.5 m/sec AND either N-terminal pro-brain natriuretic peptide (NT-pro-BNP) ≥160 pg/ml OR 6-minute walk distance \<333 m.
* Uncontrolled bacterial, viral or fungal infection in the 6 week before enrollment
* Seropositivity for human immunodeficiency virus (HIV)
* Previous hematopoietic cell transplantation (HCT)
* Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollment
* Demonstrated lack of compliance with prior medical care
* Unwilling to use approved contraception for at least 6 months following transplant
* Pregnant or breastfeeding females
* Allergy to any component of mesenchymal stromal cell (MSC) suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen.

Primary outcomes:
measure: Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs)
timeFrame: 30 days after last MSC infusion
Secondary outcomes:
measure: Primary graft rejection
timeFrame: 42 days after HCT
measure: Late graft rejection
timeFrame: One year after HCT
measure: Time to neutrophil engraftment
timeFrame: Up to one year after HCT
measure: Time to platelet engraftment
timeFrame: Up to one year after HCT
measure: Lineage specific donor chimerism
timeFrame: Up to one year after HCT
measure: Immune reconstitution
timeFrame: Up to one year after HCT
measure: Acute GVHD
timeFrame: One year after HCT
measure: Chronic GVHD
timeFrame: One year after HCT
measure: Transplant-related mortality (TRM)
timeFrame: One year after HCT
measure: Event-free survival (EFS)
timeFrame: One year after HCT
measure: Overall survival (OS)
timeFrame: One year after HCT
Other outcomes:
Locations:
Study officials:
affiliation: Emory University
name: Elizabeth Stenger, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Emory University
name: Lakshmanan Krishnamurti, MD
role: PRINCIPAL_INVESTIGATOR
References: